HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US COVID-19 Fraud: IV Drip Provider Reconsiders Claims, Bee Honey Joins List Of Unapproved Cures

Executive Summary

New York business reconsiders claiming intravenous drips of vitamin blends prevent COVID-19 infections after industry group forwarded concerns to regulators. Latest natural health remedy linked to fraudulent COVID-19 treatment claims is honey from marketers’ beehives.

You may also be interested in...



US COVID-19 Fraud: Avenova Eyelid, Eyelash Cleanser Spray Latest Target Of FDA, FTC Warning

Federal agencies submitted joint warning to NovaBay after reviewing its website and social media pages for its Avenova (hypochlorous acid 0.01%) spray solution.

Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer

Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025.  It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.

‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150643

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel